As of 2024-12-15, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -38.30. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 1,260.11 mil USD. MYGN's TTM EBITDA according to its financial statements is -32.90 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 14.6x | 13.8x |
| Forward P/E multiples | 11.1x - 17.2x | 13.9x |
| Fair Price | (3.80) - (4.70) | (4.41) |
| Upside | -126.3% - -132.6% | -130.5% |
| Date | EV/EBITDA |
| 2024-12-13 | -38.30 |
| 2024-12-12 | -38.49 |
| 2024-12-11 | -38.52 |
| 2024-12-10 | -40.82 |
| 2024-12-09 | -39.55 |
| 2024-12-06 | -40.24 |
| 2024-12-05 | -43.64 |
| 2024-12-04 | -44.31 |
| 2024-12-03 | -43.28 |
| 2024-12-02 | -44.55 |
| 2024-11-29 | -43.39 |
| 2024-11-27 | -43.42 |
| 2024-11-26 | -43.12 |
| 2024-11-25 | -41.84 |
| 2024-11-22 | -41.23 |
| 2024-11-21 | -40.21 |
| 2024-11-20 | -40.71 |
| 2024-11-19 | -39.88 |
| 2024-11-18 | -40.49 |
| 2024-11-15 | -40.57 |
| 2024-11-14 | -41.76 |
| 2024-11-13 | -42.04 |
| 2024-11-12 | -43.12 |
| 2024-11-11 | -46.27 |
| 2024-11-08 | -46.55 |
| 2024-11-07 | -47.27 |
| 2024-11-06 | -46.99 |
| 2024-11-05 | -47.10 |
| 2024-11-04 | -47.71 |
| 2024-11-01 | -48.15 |
| 2024-10-31 | -59.14 |
| 2024-10-30 | -61.38 |
| 2024-10-29 | -60.00 |
| 2024-10-28 | -59.14 |
| 2024-10-25 | -58.03 |
| 2024-10-24 | -58.72 |
| 2024-10-23 | -60.13 |
| 2024-10-22 | -60.96 |
| 2024-10-21 | -60.74 |
| 2024-10-18 | -63.10 |
| 2024-10-17 | -62.93 |
| 2024-10-16 | -64.56 |
| 2024-10-15 | -64.73 |
| 2024-10-14 | -67.83 |
| 2024-10-11 | -65.00 |
| 2024-10-10 | -62.21 |
| 2024-10-09 | -65.81 |
| 2024-10-08 | -70.21 |
| 2024-10-07 | -70.70 |
| 2024-10-04 | -71.62 |